Most recent update: Tuesday, April 7, 2020 - 09:55

Bariatric News - Cookies & privacy policy

You are here

NAFLD cost

US economic burden of fatty liver disease is $32 billion annually

Identifying the economic burden of nonalcoholic fatty liver disease brings attention to the real need for readily-available treatments that will save money and lives

Nonalcoholic fatty liver disease (NAFLD) costs the US healthcare system US$32 billion annually, according to a first-of-its-kind study by Intermountain Healthcare researchers on the economic impact of the disease. The prevalence of NAFLD, which affects roughly 100 million Americans, mirrors the rising trend of obesity in the US. Globally, one in four people are living with the disease, which is the result of a buildup of extra fat in liver cells that is not caused by alcohol and is the most common form of chronic liver disease.

"Our research is the first real-world estimate on actual healthcare utilization associated with nonalcoholic fatty liver disease in the United States," said Dr Richard Gilroy, medical director of the hepatology and liver transplant program at Intermountain Medical Center. "The results highlight the major problem we face today and the potential tsunami we will encounter if we choose to not address the causes of NAFLD now."

For comparison purposes, stroke costs the US about $34 billion annually, roughly the same amount as NAFLD, according to the Centers for Disease Control and Prevention. Results of the research were presented during the Digestive Disease Week annual conference in Washington, DC.

Identifying the economic burden of nonalcoholic fatty liver disease brings attention to the real need for readily-available treatments that will save money and lives, according to researchers.

For the study, researchers at Intermountain Medical Center in Salt Lake City examined medical records during a ten-year period (2005-2015) and identified 4,569 patients diagnosed with NAFLD. A control group of 12,486 patients with no diagnosis of the disease was identified for comparison purposes.

Using integrated data from SelectHealth, the health insurance arm of Intermountain Healthcare, researchers analysed the healthcare costs per patient and overall costs per year in both groups. The costs were then extrapolated to a national scale, which indicated an economic burden of $32 billion annually for the US.

Costs of the disease include:

  • Inpatient hospitalisation and outpatient appointments
  • Emergency room visits
  • Organ transplantation
  • Mortality
  • Medical procedures or new diagnoses
  • New medications or changes to existing medications

"We are already in an era of escalating healthcare costs and we see what was an unrecognised and infrequent disease in the 1980s, is now a major epidemic that will further drive costs in years to come," said Gilroy.

"Looking at the financial implications specifically, the results of the study also highlight the potential reduction in healthcare costs if treatments do become available," added Dr Michael Charlton, with the Intermountain Medical Center transplant programme and author of the study. "We currently have validated a predictive risk score that uses basic lab values and a patient's medical history to allow us to predict which patients are at a higher risk of developing liver damage due to the disease."

Researchers plan to use the prediction tool to get upstream of the problem at a population level by intervening with nutritional and therapeutic options, which may include clinical trials, before the patient reaches end-stage liver disease.

"At Intermountain Healthcare, we are looking to community initiatives to approach the issue as we know that change will only come through collaborations," said Gilroy. "We believe that through our strong community relationships and initiatives, we will overcome this problem."

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.